The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000620325
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
26/03/2026
Date registered
Help: Date registered
20/05/2026
Date last updated
Help: Date last updated
25/09/2026
Date data sharing statement initially provided
Help: Data sharing statement date
20/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Is Immersion the Key? A Mixed-Methods Feasibility and Acceptability Study of Virtual Reality (VR) Mindfulness in Body Dysmorphic Disorder
Scientific title
A Mixed-Methods Feasibility and Acceptability Study of Virtual Reality (VR) Mindfulness in Body Dysmorphic Disorder
Additional trial identifiers [1] 316628 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Body dysmorphic disorder 340834 0
Condition category
Condition code
Mental Health 336995 336995 0 0
Other mental health disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This is a randomized 2x2 crossover pilot clinical trial investigating brief VR and audio-based mindfulness. It will be conducted at Swinburne University (single site but state-wide recruitment), adhering to standardised guidelines (Consolidated Standards of Reporting Trials (CONSORT) and Standard Protocol Items Recommendations for Intervention Trials (SPIRIT) as well as Good Clinical Practice (GCP) guidelines. Participants will participate in both interventions, with the order of the interventions being assigned randomly in a 1:1 ratio across the two arms – VR-audio and audio-VR. The randomisation sequence will be computer-generated by the student investigator. Outcome assessments will occur at baseline and post-interventions.

VR-based mindfulness
An Oculus Quest 2 (OQ2) Head-Mounted Display will be used with the following specifications: Adreno 650 (~1.2 TFLOPS) graphics on an LCD display with a resolution of 1,832 x 1,920 pixels per eye (2,560 x 1,440 combined), a refresh rate of 72-120 Hertz and a field of view of 101 degrees. The VR-based mindfulness program will be delivered by the application TRIPP. The program consists of a female voiceover using inviting language to guide the user’s shift in attention and focus and introduces the virtual environment.
The VR-based mindfulness intervention component is fully contained within the VR headset and TRIPP application; there is no need for interaction with a researcher during the intervention process.
The intervention will be delivered through the VR headset in person.
1 x 20minutes session
The intervention will be delivered in clinical research space at Swinburne University of Technology
Trained research staff members will sit with participants to perform well-being checks. Senior researcher will be contacted if any further support is required.

Wash out period
There will be a 'wash out' period of 20 minutes between the two treatments.
Intervention code [1] 333308 0
Treatment: Other
Intervention code [2] 333580 0
Behaviour
Description of the comparator or control
Comparator (conventional treatment):
Audio-based mindfulness
Participants will be fitted with headphones for the delivery of the audio-guided body scan. The session consists of a female voiceover using inviting language to guide the user’s shift in attention and focus on breath awareness and body scan will be identical to the VR condition.
The conventional treatment component is fully contained within the TRIPP application; there is no need for interaction with a researcher during the intervention process.
The conventional treatment will be delivered through headphones in person.
1 x 20minutes session
The conventional treatment will be delivered in clinical research space at Swinburne University of Technology
Trained research staff members will sit with participants to perform well-being checks. Senior researcher will be contacted if any further support is required.
Control group
Active

Outcomes
Primary outcome [1] 344523 0
Feasibility of VR-based mindfulness
Timepoint [1] 344523 0
Post completion of each intervention
Primary outcome [2] 344869 0
Acceptability of each mindfulness condition
Timepoint [2] 344869 0
semi-structured interview: post each intervention overall acceptability interview: post overall intervention
Primary outcome [3] 344870 0
Perceived acceptability of intervention
Timepoint [3] 344870 0
baseline of each intervention
Secondary outcome [1] 458173 0
State mindfulness
Timepoint [1] 458173 0
baseline and post-completion of each intervention
Secondary outcome [2] 459576 0
Emotional regulation
Timepoint [2] 459576 0
baseline and post-completion of each intervention
Secondary outcome [3] 459577 0
Body-image concerns
Timepoint [3] 459577 0
baseline and post-completion of each intervention
Secondary outcome [4] 459578 0
Heart rate variability
Timepoint [4] 459578 0
Duration of intervention
Secondary outcome [5] 459579 0
Galvanic Skin Response
Timepoint [5] 459579 0
Duration of the intervention

Eligibility
Key inclusion criteria
Participants will i) be aged between 18-65 years (inclusive); ii) have a primary diagnosis of BDD according to the SCID-5 BDD-DM (diagnostic module); iii) score greater than or equal to 15 on the BDD-YBOCS (to ensure at least mild symptom severity); iv) have been stabilised on psychiatric medications, if prescribed, for 8weeks; and v) have capacity to consent to the study. Further, BDD patients frequently report co-morbid depression, social anxiety and psychoses. To ensure our sample is representative, participants with co-morbidities will be included and may be engaged in current psychological or psychiatric treatment either for BDD or comorbid psychological symptoms.
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Participants will be excluded if i) uncorrected hearing and/or visual impairments are present; ii) they are unable to meaningfully converse in, or read, English; iii) previous or current significant head and neck injuries; iv) they have a history of sever psychopathology, substance dependence disorders, or psychotic disorders; vi) lifetime; v) have lifetime history of neurological or ocular conditions, vi) have an ongoing dialectical behaviour therapy and acceptance and commitment therapy, or therapy that actively includes mindfulness.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created
by computer software (i.e. computerised sequence
generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Recruitment data. Descriptive statistics will be used to summarise assessments of recruitment (including successful screening), complaisance, drop-out and intervention completion.
Feasibility and acceptability data. Primary Outcomes: Regression analyses will be performed to determine whether the clinical profile or intervention modality can explain the drop out or compliance data. Thematic analysis will be conducted on the semi-structured interviews by identifying codes and summarizing participant responses into themes.
Clinical data. Secondary Outcomes Baseline values for the two groups will be compared using chi-squared tests of association for categorical variables (or Fisher’s exact test for small samples) and univariate ANOVA tests (or Kruskal-Wallis tests) for continuous variables. Any significant clinical differences are unlikely, due to the random allocation of participants across conditions. For the secondary analysis, a Linear Mixed Effects (LME) with individuals entered as random effect to account for individual differences. The dependent variable will be SMS, S-DERS, mDES, SBAS-2 and BISS scores. The independent variables will be Group (VR versus audio) and Order (VR-audio vs audio-VR).
Physiological data. Secondary Outcomes Summary metrics will be computed for HRV and GSR. The same analytic approach will be used for the secondary physiological outcomes

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 321245 0
University
Name [1] 321245 0
Swinburne University of Technology
Country [1] 321245 0
Australia
Primary sponsor type
University
Name
Swinburne University of Technology
Address
Country
Australia
Secondary sponsor category [1] 323955 0
None
Name [1] 323955 0
Address [1] 323955 0
Country [1] 323955 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319772 0
Swinburne University of Technology Human Research Ethics Committee
Ethics committee address [1] 319772 0
Ethics committee country [1] 319772 0
Australia
Date submitted for ethics approval [1] 319772 0
27/02/2026
Approval date [1] 319772 0
22/04/2026
Ethics approval number [1] 319772 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148350 0
Prof Susan Rossell
Address 148350 0
Swinburne University of Technology, John St, Hawthorn VIC 3122
Country 148350 0
Australia
Phone 148350 0
+61 3 92148173
Fax 148350 0
Email 148350 0
Contact person for public queries
Name 148351 0
Iris He
Address 148351 0
Swinburne University of Technology, John St, Hawthorn VIC 3122
Country 148351 0
Australia
Phone 148351 0
+61 493643397
Fax 148351 0
Email 148351 0
Contact person for scientific queries
Name 148352 0
Iris He
Address 148352 0
Swinburne University of Technology, John St, Hawthorn VIC 3122
Country 148352 0
Australia
Phone 148352 0
+61 493643397
Fax 148352 0
Email 148352 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Only group results will be available, as within the consent form



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.